Tags kidney disease kidney disease Kidney diseases such as IgA nephropathy, and drugs for them.
Theme · 2 companies · 0 report it as a revenue line
In development“renal diseases, including IgAN, C3G and IC-MPGN”
Latest 424B4 final IPO prospectus Positive Pre-revenue · Filed Sep 25
Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development
In development“Povetacicept’s IgAN application is under FDA priority review, with a November 30, 2026 PDUFA date; approval would give Vertex its first commercial nephrology product.”
Latest 10-Q Q3 FY2026 Positive · Filed Nov 3
Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.
Revenue $3.4B YoY +11.8% Net income $653.6M YoY −39.6% Latest 8-K Positive Earnings Guidance raised Impairment / charge · Filed Nov 2
CF therapies anchor growth as FY2026 revenue guidance rises to $13.15B–$13.25B; Crinetics acquisition costs weigh on GAAP earnings.
Latest 8-K Leadership change · Filed Oct 20
Daniel Brennan joins the board and Audit and Finance Committee with a $400K RSU award vesting in October 2027.
Latest 8-K CEO/CFO change · Filed Sep 1
Jonathan Poole becomes CFO effective Jan. 1, 2027; Charles F. Wagner leaves the CFO role and remains COO.
Latest 8-K Positive Guidance Deal pending Clinical / regulatory decision · Filed Jul 6
Agreement to buy Crinetics for $85/share in cash would add PALSONIFY and late-stage endocrine medicines
No companies have a recent 8-K matching these events. Show all 8-K events
No companies in the selected roles.